WASHINGTON — The Supreme Court will next week consider a case that has the potential to upend how drug companies can defend themselves from patient lawsuits.

The case, Merck Sharp & Dohme Corp. v. Doris Albrecht, began as a collection of lawsuits by more than a thousand patients who used the osteoporosis drug Fosamax. The patients say the drug maker failed to adequately warn them that taking the drug might make them more likely to fracture their femurs.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • this seems pretty black and white. Merck cannot communicate anything off-label about their drugs. They asked FDA to update their label. FDA determined there was insufficient evidence to make that update, and it appears any update related to bone fractures.
    I suspect if the lower court had ruled MSD wasn’t liable, the SCOTUS would not have taken this case. They took it to straighten out a clear wrong decision.
    I feel terrible for the suffering, including I assume disability, that some patients taking Fosamax have experienced. And FDA should probably have acted differently. If anyone is at blame here it’s them. But there’s no $$ in suing FDA, is there?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy